3.16

3.27% 0.10

After Hours: 3.16

Collplant Biotechnologies Ltd (CLGN)

Overview News Price History Option Chain Discussions Forecast

Collplant Biotechnologies Ltd stock is traded at $3.16, with a volume of 1,382. It is up +3.27% in the last 24 hours and down -16.15% over the past month. CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.

Previous Close:

$3.06

Open:

$3.15

24h Volume:

1,382

Relative Volume:

0.16

Market Cap:

$36.20M

Revenue:

$10.96M

Net Income/Loss:

$-7.02M

P/E Ratio:

-4.9375

EPS:

-0.64

Net Cash Flow:

$-3.72M

1W Performance:

+3.27%

1M Performance:

-16.15%

6M Performance:

-36.92%

1Y Performance:

-37.62%

1-Day Range:

$3.15

$3.25

1-Week Range:

$3.05

$3.38

52-Week Range:

$3.00

$6.75

Collplant Biotechnologies Ltd Stock (CLGN) Company Profile

Name

Collplant Biotechnologies Ltd

Sector

Healthcare (1169)

Industry

Biotechnology (679)

Phone

Address

Employee

Twitter

@CollplantBio

Next Earnings Date

2024-12-27

Latest SEC Filings

CLGN's Discussions on Twitter

Compare CLGN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CLGN Collplant Biotechnologies Ltd	3.16	36.20M	10.96M	-7.02M	-3.72M	-0.64
VRTX Vertex Pharmaceuticals Inc	502.92	129.14B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	680.61	74.41B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	581.21	35.31B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	241.75	31.30B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	254.57	27.35B	3.32B	-860.46M	-1.04B	-8.32

Collplant Biotechnologies Ltd Stock (CLGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-17-23	Initiated	Alliance Global Partners	Buy

Collplant Biotechnologies Ltd Stock (CLGN) Latest News

Mar 05, 2025

Collplant stock hits 52-week low at $3.07 amid market challenges By Investing.com - Investing.com South Africa

Mar 05, 2025

Collplant stock hits 52-week low at $3.07 amid market challenges - Investing.com India

Mar 05, 2025

Feb 25, 2025

Collplant stock hits 52-week low at $3.24 amid market challenges - Investing.com India

Feb 25, 2025

Collplant stock hits 52-week low at $3.24 amid market challenges By Investing.com - Investing.com South Africa

Feb 25, 2025

Israel-based CollPlant expands distribution for VergenixSTR in Europe and Asia - BSA bureau

Feb 25, 2025

Feb 24, 2025

CollPlant expands VergenixSTR distribution in Europe and Asia By Investing.com - Investing.com Australia

Feb 24, 2025

CollPlant expands European and Asian distribution of soft tissue repair matrix - Yahoo Finance

Feb 24, 2025

CollPlant Expands Vergenix STR Distribution Across Europe And Asia - Nasdaq

Feb 24, 2025

Medical Breakthrough: CollPlant's Tendon Treatment Enters 4 New MarketsWhy It Matters - StockTitan

Feb 24, 2025

Feb 14, 2025

D. Boral Capital Reaffirms “Buy” Rating for CollPlant Biotechnologies (NASDAQ:CLGN) - Defense World

Feb 14, 2025

Feb 12, 2025

CollPlant secures U.S. patent for dermal filler - Investing.com India

Feb 12, 2025

CollPlant secures U.S. patent for dermal filler By Investing.com - Investing.com Australia

Feb 12, 2025

CollPlant Biotechnologies Provides a Corporate Update - PR Newswire

Feb 12, 2025

Feb 10, 2025

Tissue Engineering Market: Key Player Profiles, Industry US$ - openPR

Feb 10, 2025

Feb 06, 2025

CollPlant Biotechnologies (NASDAQ:CLGN) Earns Buy Rating from D. Boral Capital - Defense World

Feb 06, 2025

Jan 20, 2025

Contrasting CollPlant Biotechnologies (NASDAQ:CLGN) and Pathfinder Cell Therapy (OTCMKTS:PFND) - Defense World

Jan 20, 2025

Dec 01, 2024

CLGN (CollPlant Biotechnologies) 50-Day SMA : $4.31 (As of Dec. 01, 2024) - GuruFocus.com

Dec 01, 2024

Nov 30, 2024

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q3 2024 Earnings Call Transcript - MSN

Nov 30, 2024

Nov 28, 2024

CLGNCollPlant Biotechnologies Ltd Ordinary Shares Latest Stock News & Market Updates - StockTitan

Nov 28, 2024

CollPlant Biotechnologies Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St

Nov 28, 2024